Study summary
A shot every three months that silences the TTR gene lowered the risk of death by about a third
0.65hazard ratio for death from any cause through 42 months
What was tested
Vutrisiran, an RNA-silencing injection given every 3 months that stops the liver making transthyretin (TTR), against placebo, for transthyretin amyloid cardiomyopathy.
What they found
- Risk of death from any cause through 42 months was 35% lower (hazard ratio 0.65).
- Death or recurrent heart events were 28% lower (hazard ratio 0.72).
- Walking distance and quality of life declined less.
What it means
Added a second type of drug, gene silencing, to the stabilizers already used.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.